{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:23:19Z","timestamp":1760217799847},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"\"Victor Babes\" University of Medicine and Pharmacy","award":["PII-C4-TC-2016\/16441-09"],"award-info":[{"award-number":["PII-C4-TC-2016\/16441-09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s11845-017-1580-5","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T02:56:08Z","timestamp":1487645768000},"page":"621-629","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension"],"prefix":"10.1007","volume":"186","author":[{"given":"V.","family":"Buda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Andor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cristescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Voicu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cochera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tuduce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Petrescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Tomescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"1580_CR1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.114.03575","volume":"64","author":"RP Brandes","year":"2014","unstructured":"Brandes RP (2014) Endothelial dysfunction and hypertension. Hypertension 64:924\u2013928","journal-title":"Hypertension"},{"issue":"1","key":"1580_CR2","first-page":"58","volume":"55","author":"M Andor","year":"2005","unstructured":"Andor M, Tomescu M (2005) Endothelial dysfunction\u2014methods of assessment and pharmacological approach in cardiovascular diseases. TMJ 55(1):58\u201363","journal-title":"TMJ"},{"issue":"3","key":"1580_CR3","first-page":"291","volume":"2014","author":"RJ Widmer","year":"2014","unstructured":"Widmer RJ, Lerman A (2014) Endothelial dysfunction and cardiovascular disease. Global Cardiol Sci Pract\u00a02014(3):291\u2013308","journal-title":"Global Cardiol Sci Pract"},{"key":"1580_CR4","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1161\/01.CIR.0000089190.95415.9F","volume":"108","author":"PE Szmitko","year":"2003","unstructured":"Szmitko PE, Wang CH, Weisel RD et al (2003) New markers of inflammation and endothelial cell activation part I. Circulation 108:1917\u20131923","journal-title":"Circulation"},{"key":"1580_CR5","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1161\/01.CIR.0000089093.75585.98","volume":"108","author":"PE Szmitko","year":"2003","unstructured":"Szmitko PE, Wang CH, Weisel RD et al (2003) Biomarkers of vascular disease linking inflammation to endothelial activation part II. Circulation 108:2041\u20132048","journal-title":"Circulation"},{"key":"1580_CR6","doi-asserted-by":"crossref","unstructured":"Inoue K, Kodama T, Daida H (2012) Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med (Hindawi Publishing Corporation ID 657025)","DOI":"10.1155\/2012\/657025"},{"key":"1580_CR7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/ndt\/gfs448","volume":"28","author":"M Lech","year":"2013","unstructured":"Lech M, Rommele C, Anders HJ (2013) Pentraxins in nephrology: C-reactive protein, serum amyloid P and pentraxin-3. Nephrol Dial Transplant 28:803\u2013811","journal-title":"Nephrol Dial Transplant"},{"key":"1580_CR8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jjcc.2011.03.006","volume":"58","author":"N Kume","year":"2011","unstructured":"Kume N, Mitsuoka H, Hayashida K, Tanaka M (2011) Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol 58:38\u201345","journal-title":"J Cardiol"},{"key":"1580_CR9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jth.12557","volume":"12","author":"NS Jenny","year":"2014","unstructured":"Jenny NS, Blumenthal RS, Kronmal RA, Rotter JI, Siscovick DS, Psaty BM (2014) Associations of pentraxin 3 with cardiovascular disease: the multi-ethnic study of atherosclerosis. J Thromb Hemost 12:999\u20131005","journal-title":"J Thromb Hemost"},{"key":"1580_CR10","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2010.10.018","volume":"57","author":"J Matsubara","year":"2011","unstructured":"Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M et al (2011) Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 57:861\u2013869","journal-title":"J Am Coll Cardiol"},{"key":"1580_CR11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/hrt.2003.032847","volume":"91","author":"D Tousoulis","year":"2005","unstructured":"Tousoulis D, Antoniades C, Stefanadic C (2005) Evaluating endothelial function in humans: a guide to invasive and non invasive techniques. Heart 91:553\u2013558","journal-title":"Heart"},{"key":"1580_CR12","doi-asserted-by":"crossref","unstructured":"Touboul PJ, Hennerici MG, Meairs S et al (2012) Mannheim carotid intima-media thickness and plaque consensus (2004\u20132006\u20132011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European stroke conferences, Mannheim, 2004, Brussels, 2006, and Hamburg, 2011. Cerebrovasc Dis 34(4):290\u2013296","DOI":"10.1159\/000343145"},{"key":"1580_CR13","first-page":"12","volume":"10","author":"A Husain","year":"2011","unstructured":"Husain A, Azim S, Mitra M, Bhasin PS (2011) A review on candesartan: pharmacological and pharmaceutical profile. J Appl Pharm Sci 10:12\u201317","journal-title":"J Appl Pharm Sci"},{"key":"1580_CR14","first-page":"509","volume":"3","author":"V Buda","year":"2014","unstructured":"Buda V, Andor M, Cristescu C, Voicu M, Suciu L, Suciu M, Tomescu M (2014) Blockers of the RAA system: perindopril and candesartan and their implication on endothelial dysfunction. Med Evol 3:509\u2013517","journal-title":"Med Evol"},{"key":"1580_CR15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","volume":"103","author":"M Burnier","year":"2001","unstructured":"Burnier M (2001) Angiotensin II type 1 receptor blockers. Circulation 103:904\u2013912","journal-title":"Circulation"},{"key":"1580_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/1470320310370852","author":"S Miura","year":"2011","unstructured":"Miura S, Karnik SS, Saku K (2011) Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin\u2013Angiotensin\u2013Aldosterone Syst. doi: 10.1177\/1470320310370852","journal-title":"J Renin\u2013Angiotensin\u2013Aldosterone Syst"},{"key":"1580_CR17","first-page":"1","volume":"36","author":"MA Munger","year":"2011","unstructured":"Munger MA (2011) Use of angiotensin receptor blockers in cardiovascular protection. Curr Evid Future Dir P&T 36:1","journal-title":"Curr Evid Future Dir P&T"},{"key":"1580_CR18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/pr.112.007278","volume":"65","author":"MC Michel","year":"2013","unstructured":"Michel MC, Foster C, Brunner HR, Liu L (2013) A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 65:809\u2013848","journal-title":"Pharmacol Rev"},{"key":"1580_CR19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2318-9-48","volume":"9","author":"I Hajjar","year":"2009","unstructured":"Hajjar I, Hart M, Milberg W et al (2009) The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr 9:48","journal-title":"BMC Geriatr"},{"key":"1580_CR20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1475-2840-9-38","volume":"9","author":"Y Nishida","year":"2010","unstructured":"Nishida Y, Takahashi Y, Nakayama T et al (2010) Effect of\u00a0candesartan\u00a0monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 9:38","journal-title":"Cardiovasc Diabetol"},{"key":"1580_CR21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2006.08.062","volume":"552","author":"S Zorad","year":"2006","unstructured":"Zorad S, Dou JT, Benicky J, Hutanu D et al (2006) Long-term angiotensin II AT1 _receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPAR\u03b3. Eur J Pharmacol 552:112\u2013122","journal-title":"Eur J Pharmacol"},{"key":"1580_CR22","first-page":"2397","volume":"5","author":"SA Doggrell","year":"2004","unstructured":"Doggrell SA (2004) Telmisartan\u2014killing two birds with one stone. Pharmacotherapy 5:2397\u20132400","journal-title":"Pharmacotherapy"},{"key":"1580_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-6-26","volume":"6","author":"N Kitamura","year":"2007","unstructured":"Kitamura N, Takahashi Y, Yamadate S, Asai S (2007) Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 6:26","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1580_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0735-1097(03)00846-5","volume":"42","author":"KK Kwang","year":"2003","unstructured":"Kwang KK, Jeong JA et al (2003) Pleiotropic effects of ang II receptor blocker in hypertensive patients. J Am Coll Cardiol 42(5):905\u2013910","journal-title":"J Am Coll Cardiol"},{"key":"1580_CR25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, Hansson L, Skoog I et al (2003) SCOPE study groups: the study on cognitive and prognosis in the elderly: principal results of a randomized double-blind interventional trial. Hypertension 21:875\u2013886","journal-title":"Hypertension"},{"key":"1580_CR26","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1161\/01.STR.0000075777.18006.89","volume":"34","author":"J Schrader","year":"2003","unstructured":"Schrader J, Luders S, Kulschewski A et al (2003) Acute candesartan cilexitil therapy in stroke survivors study group: the-ACCESS study: evaluation of acute candesartan cilexitil therapy in stroke survivors. Stroke 34:1699\u20131703","journal-title":"Stroke"},{"key":"1580_CR27","unstructured":"Pfeffer MA, Swedberg K et al (2016) CHARM investigators and committees: effect of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362:759\u2013766"},{"issue":"7","key":"1580_CR28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2215\/CJN.01110210","volume":"5","author":"MI Yilmaz","year":"2010","unstructured":"Yilmaz MI, Carreo JJ, Martin-Ventura JL et al (2010) Combined therapy with renin\u2013angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3 and flow-mediated dilatation. Clin J Am Soc Nephrol 5(7):1174\u20131181","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1580_CR29","first-page":"382","volume":"64","author":"V Buda","year":"2016","unstructured":"Buda V, Andor M, Cristescu C et al (2016) The influence of perindopril on PTX3 plasma levels in hypertensive patients with endothelial dysfunction. Farmacia 64(3):382\u2013389","journal-title":"Farmacia"},{"issue":"5","key":"1580_CR30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/gerona\/glq030","volume":"65","author":"Y Yano","year":"2010","unstructured":"Yano Y, Matsuda S, Hatakeyama K et al (2010) Plasma pentraxin 3 but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci 65(5):547\u2013552","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"1580_CR31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2215\/CJN.04330808","volume":"4","author":"MI Yilmaz","year":"2009","unstructured":"Yilmaz MI, Axelsson J, Sonmez A et al (2009) Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 4(3):535\u2013541","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1580_CR32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/10641963.2012.739237","volume":"35","author":"M Unlu","year":"2013","unstructured":"Unlu M, Karaman M, Ahmet SA et al (2013) The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. Clin Exp Hypertens 35(6):418\u2013423","journal-title":"Clin Exp Hypertens"},{"issue":"4","key":"1580_CR33","first-page":"298","volume":"12","author":"A Parlak","year":"2012","unstructured":"Parlak A, Aydogan U, Iyisoy A et al (2012) Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study. Anatol J Cardiol 12(4):298\u2013304","journal-title":"Anatol J Cardiol"},{"issue":"17","key":"1580_CR34","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA","volume":"131","author":"A Carrizzo","year":"2015","unstructured":"Carrizzo A, Lenzi P, Procaccini C et al (2015) Pentraxin 3 induces vascular endothelial dysfunction through a P-selectin\/matrix metalloproteinase-1 pathway. Circulation 131(17):1495\u20131505. doi: 10.1161\/CIRCULATIONAHA","journal-title":"Circulation"},{"issue":"2","key":"1580_CR35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1536\/ihj.13-253","volume":"55","author":"T Yasunaga","year":"2014","unstructured":"Yasunaga T, Ikeda S, Koga S et al (2014) Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein. Int Heart J 55(2):160\u2013164","journal-title":"Int Heart J"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-017-1580-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-017-1580-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-017-1580-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T22:19:08Z","timestamp":1568845148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-017-1580-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s11845-017-1580-5","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}